GlassScriptPhysician profile
Naveen Kumar Ambati
NPI 1922749829
$2,983.02
in general payments reported to CMS, 2019-2025
12 companies · $999 in 2025
The $999 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.56 · 2023: $754 · 2024: $1,188 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,532.79 | 2023-2025 | Clareon, Hydrus Microstent, Centurion |
| Regeneron Healthcare Solutions, INC. | $416.80 | 2022-2025 | Eylea Hd |
| Biotissue Holdings INC. | $214.50 | 2024 | |
| Alimera Sciences, INC. | $161.07 | 2024 | Yutiq, Iluvien |
| Sight Sciences, INC. | $142.57 | 2024 | Omni Surgical System |
| Regeneron Pharmaceuticals, INC. | $138.46 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $124.83 | 2023 | Syfovre |
| Astellas Pharma US INC | $99.70 | 2023 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $52.94 | 2024 | Tecnis Simplicity |
| Harrow Eye, LLC | $44.30 | 2024 | Vevye |
| Mallinckrodt Hospital Products INC. | $34.74 | 2025 | Acthar |
| Dutch Ophthalmic, USA | $20.32 | 2025 | Eva, Combined Machine, Tissueblue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Kumar Ambati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.